Piteau S, Olver A, Kim SJ et al (2007) Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat
During freeze-drying, the peptides are gently frozen and placed under low pressure so the water turns straight from ice into vapor
Protocol approach 2: gut-focused autoimmune support (BPC-157 plus KPV) Goal: Restore gut barrier integrity and reduce intestinal inflammation Components: BPC-157 : 200-300 mcg twice daily, orally or subcutaneously near the abdomen (promotes mucosal healing, angiogenesis) KPV: 200-500 mcg daily, orally (NF-kB inhibition, cytokine reduction, PepT1-mediated gut absorption) Rationale: For autoimmune conditions with significant gastrointestinal involvement, including IBD, celiac-associated inflammation, or any autoimmune condition complicated by leaky gut, this combination addresses both the physical barrier damage (BPC-157) and the inflammatory signaling (KPV)
And with Limitless Biotech, those answers aren't as clear-cut as I'd like them to be
